

Philippe Pouletty
Chairman of France Biotech
Founder and General Partner of Truffle Capital



MD, 50, is Founder and General Partner of Truffle Capital, a leading venture fund based in Paris, and Chairman of France Biotech, the French biotechnology association. He founded three biotechnology companies in North America and Europe: SangStat (which became a world leader in the transplant rejection market with revenues of over \$100 million); Conjuchem (TSE); and DrugAbuse Sciences; which collectively achieved a combined market capitalization of over \$900 million.

Inventor of 29 patents, Dr. Pouletty is on the Board of Directors of twelve biotechnology and medical device companies in Europe and North America (BMD, Conjuchem, Cytomics, Deinove, Innate Pharma, Immune Targeting Systems Ltd, Neovacs, Pharnext, Symetis, Theraclion, Vexim, and Wittycell).

He triggered several government initiatives in France and Europe, including the 1999 SAS legislation to simplify corporate law, “Plan Biotech 2002” to boost biotechnology, and the Young Innovative Enterprise status (JEI) which provides broad tax exemptions to innovative companies in France and is being adopted by other European countries. Dr Pouletty was a member of the Strategic Council for the Attractivity of France, chaired by the Prime Minister.

He is Chevalier de la Légion d’Honneur, Laureate of the American Liver Foundation, Medical Doctor (University of Paris VI), and former postdoctoral fellow at Stanford University.